Phase I Clinical Evaluation of a Neutralizing Monoclonal Antibody Against Epidermal Growth Factor Receptor in Advanced Brain Tumor Patients: Preliminary Study
- 1 April 2001
- journal article
- clinical trial
- Published by Mary Ann Liebert Inc in Hybridoma
- Vol. 20 (2) , 131-136
- https://doi.org/10.1089/02724570152057634
Abstract
High levels of growth factors and their receptors have been demonstrated in human tumors. Gliomas and meningiomas are characterized by overexpression of epidermal growth factor receptor (EGF-R). Ior egf/r3, is a neutralizing murine monoclonal antibody (MAb) against EGF-R, and was generated at the Cuban Institute of Oncology. The antibody recognizes EGF-R with high affinity, inhibiting tyrosine kinase activation. A clinical trial was conducted in brain tumor patients to evaluate toxicity, immunogenicity, and clinical benefit of escalating doses of the antibody. Nine patients with histologically confirmed gliomas or meningiomas, who had active or recurrent disease after receiving conventional treatment, received four intravenous doses of ior egf/r3. Total dosages ranged from 160 to 480 mg. As inclusion criteria, radioimmunoscintigraphy with the same MAb labeled with 99mTechnetium (99mTc) was performed. Immune response against the murine antibody was also evaluated. After four doses of ior egf/r3 MAb, no significant toxicity was found, except in one patient who developed a grade 4 allergic adverse event. This reaction was probably related with previous sensitization to the same MAb and the development of human anti-mouse antibodies (HAMA) response. Despite no major objective antitumor responses, eight patients had stable disease on the 6-month evaluation, and two patients remain alive after four years of MAb therapy.Keywords
This publication has 25 references indexed in Scilit:
- Phenotype vs Genotype in the Evolution of Astrocytic Brain TumorsToxicologic Pathology, 2000
- Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomasNeuropathology and Applied Neurobiology, 1998
- Association of EGFR Gene Amplification and CDKN2 (p16/MTS1) Gene Deletion in Glioblastoma MultiformeBrain Pathology, 1997
- A Phase I Study of an Anti-epidermal Growth Factor Receptor Monoclonal Antibody for the Treatment of Malignant GliomasNeurosurgery, 1996
- Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55 900) in patients with recurrent malignant gliomasEuropean Journal Of Cancer, 1996
- Epidermal Growth Factor Receptor 425 Monoclonal Antibodies Radiolabeled with Iodine-125 in the Adjuvant Treatment of High-Grade AstrocytomasHybridoma, 1995
- Utilization of 125I monoclonal antibody in the management of primary glioblastoma multiformeRadiation Oncology Investigations, 1995
- Harmonisation in PharmacovigilanceDrug Safety, 1994
- Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: A phase II trialInternational Journal of Radiation Oncology*Biology*Physics, 1992
- A new monoclonal antibody for detection of EGF‐receptors in western blots and paraffin‐embedded tissue sectionsJournal of Cellular Biochemistry, 1992